Sagimet Biosciences Inc.

Sagimet Biosciences Inc. is involved in clinical research centered on impaired hepatic function, with interest in how mild, moderate, and severe hepatic impairment relate to normal liver function. The study population includes healthy volunteers alongside participants with Child-Pugh A, Child-Pugh B, and Child-Pugh C classifications.

• Normal hepatic function
• Mild hepatic impairment
• Moderate hepatic impairment
• Severe hepatic impairment

The sponsor’s research activity is directed toward understanding hepatic impairment across a range of liver disease severity categories in a human pharmacology setting.